Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD.

ABSTRACT:

Context

Recombinant human growth hormone (rhGH) is approved for treatment of pediatric growth hormone deficiency (GHD), with greatest growth responses observed in those with severe GHD. Orally administered GH secretagogues (GHS) may be useful treatment in patients with moderate GHD. Distinguishing children with severe vs moderate GHD could identify children who would be better treated with rhGH or GHS.

Objectives

Evaluate baseline insulin-like growth factor-I (IGF-I) and stimulated peak GH response as predictors of 12-month height velocity (HV) in children with GHD.

Design

Data on children with GHD were analyzed in a legacy data base (GeNeSIS data).

Participants

514 naïve to rhGH-treatment, prepubertal children with idiopathic isolated GHD for whom stimu

SUBMITTER: Blum WF 

PROVIDER: S-EPMC8101276 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature